News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optimer Pharmaceuticals, Inc. (OPTR) to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results


5/2/2013 7:38:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, May 9. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the first quarter and provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICIDĀ® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR. The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES